메뉴 건너뛰기




Volumn 28, Issue 4, 2014, Pages

Appropriate management of molecular subtypes of diffuse large B-cell lymphoma

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR EZH2; VINCRISTINE;

EID: 84899442614     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (21)

References (73)
  • 2
    • 0037142053 scopus 로고    scopus 로고
    • The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    • Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
    • (2002) N Engl J Med , vol.346 , pp. 1937-1947
    • Rosenwald, A.1    Wright, G.2    Chan, W.C.3
  • 3
    • 51649111684 scopus 로고    scopus 로고
    • Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
    • Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105:13520-13525.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 13520-13525
    • Lenz, G.1    Wright, G.W.2    Emre, N.C.3
  • 4
    • 0032953365 scopus 로고    scopus 로고
    • Molecular pathogenesis of B cell malignancy: The role of BCL-6
    • discussion 63-5
    • Dalla-Favera R, Migliazza A, Chang CC, et al. Molecular pathogenesis of B cell malignancy: the role of BCL-6. Curr Top Microbiol Immunol. 1999;246:257-263; discussion 63-5.
    • (1999) Curr Top Microbiol Immunol , vol.246 , pp. 257-263
    • Dalla-Favera, R.1    Migliazza, A.2    Chang, C.C.3
  • 5
    • 0031726359 scopus 로고    scopus 로고
    • Inhibition of fas death signals by FLIPs
    • Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol. 1998;10:552-558.
    • (1998) Curr Opin Immunol , vol.10 , pp. 552-558
    • Tschopp, J.1    Irmler, M.2    Thome, M.3
  • 6
    • 0034598746 scopus 로고    scopus 로고
    • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    • Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
    • (2000) Nature , vol.403 , pp. 503-511
    • Alizadeh, A.A.1    Eisen, M.B.2    Davis, R.E.3
  • 7
    • 57149089307 scopus 로고    scopus 로고
    • Stromal gene signatures in large B-cell lymphomas
    • Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
    • (2008) N Engl J Med , vol.359 , pp. 2313-2323
    • Lenz, G.1    Wright, G.2    Dave, S.S.3
  • 8
    • 84865962469 scopus 로고    scopus 로고
    • Gray zone lymphoma: Better treated like Hodgkin lymphoma or mediastinal large B-cell lymphoma?
    • Dunleavy K, Grant C, Eberle FC, et al. Gray zone lymphoma: better treated like Hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep. 2012;7:241-247.
    • (2012) Curr Hematol Malig Rep , vol.7 , pp. 241-247
    • Dunleavy, K.1    Grant, C.2    Eberle, F.C.3
  • 9
    • 0141672946 scopus 로고    scopus 로고
    • Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    • Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-862.
    • (2003) J Exp Med , vol.198 , pp. 851-862
    • Rosenwald, A.1    Wright, G.2    Leroy, K.3
  • 10
    • 0027394689 scopus 로고
    • Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
    • Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
    • (1993) N Engl J Med , vol.328 , pp. 1002-1006
    • Fisher, R.I.1    Gaynor, E.R.2    Dahlberg, S.3
  • 11
    • 3242802160 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
    • Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634-641.
    • (2004) Blood , vol.104 , pp. 634-641
    • Pfreundschuh, M.1    Trumper, L.2    Kloess, M.3
  • 12
    • 3042813710 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
    • Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-633.
    • (2004) Blood , vol.104 , pp. 626-633
    • Pfreundschuh, M.1    Trumper, L.2    Kloess, M.3
  • 13
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
    • (2006) Lancet Oncol , vol.7 , pp. 379-391
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 14
    • 38549147027 scopus 로고    scopus 로고
    • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
    • Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-116.
    • (2008) Lancet Oncol , vol.9 , pp. 105-116
    • Pfreundschuh, M.1    Schubert, J.2    Ziepert, M.3
  • 15
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
    • (2002) N Engl J Med , vol.346 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 16
    • 80054750428 scopus 로고    scopus 로고
    • R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma
    • Abstr 8000
    • Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol. 2011;29(suppl):Abstr 8000.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Cunningham, D.1    Smith, P.2    Mouncey, P.3
  • 17
    • 84878112490 scopus 로고    scopus 로고
    • Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles
    • Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817-1826.
    • (2013) Lancet , vol.381 , pp. 1817-1826
    • Cunningham, D.1    Hawkes, E.A.2    Jack, A.3
  • 18
    • 84876987456 scopus 로고    scopus 로고
    • Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial
    • Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525-533.
    • (2013) Lancet Oncol , vol.14 , pp. 525-533
    • Delarue, R.1    Tilly, H.2    Mounier, N.3
  • 19
    • 82255186682 scopus 로고    scopus 로고
    • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial
    • Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858-1867.
    • (2011) Lancet , vol.378 , pp. 1858-1867
    • Récher, C.1    Coiffier, B.2    Haioun, C.3
  • 20
    • 84877116726 scopus 로고    scopus 로고
    • Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study
    • Holte H, Leppa S, Bjorkholm M, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24:1385-1392.
    • (2013) Ann Oncol , vol.24 , pp. 1385-1392
    • Holte, H.1    Leppa, S.2    Bjorkholm, M.3
  • 21
    • 0037089314 scopus 로고    scopus 로고
    • Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy
    • Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685-2693.
    • (2002) Blood , vol.99 , pp. 2685-2693
    • Wilson, W.H.1    Grossbard, M.L.2    Pittaluga, S.3
  • 22
    • 84860573088 scopus 로고    scopus 로고
    • A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
    • Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97:758-765.
    • (2012) Haematologica , vol.97 , pp. 758-765
    • Wilson, W.H.1    Jung, S.H.2    Porcu, P.3
  • 23
    • 77956450385 scopus 로고    scopus 로고
    • The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma
    • Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(suppl 1):28-33.
    • (2010) Leuk Lymphoma , vol.51 , Issue.SUPPL. 1 , pp. 28-33
    • Dunleavy, K.1    Mikhaeel, G.2    Sehn, L.H.3
  • 24
    • 33845902264 scopus 로고    scopus 로고
    • Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: Results from a prospective observational study
    • Garcia-Suarez J, Banas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136:276-285.
    • (2007) Br J Haematol , vol.136 , pp. 276-285
    • Garcia-Suarez, J.1    Banas, H.2    Arribas, I.3
  • 25
    • 84873093053 scopus 로고    scopus 로고
    • Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma
    • Garcia-Suarez J, Flores E, Callejas M, et al. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma. Br J Haematol. 2013;160:510-514.
    • (2013) Br J Haematol , vol.160 , pp. 510-514
    • Garcia-Suarez, J.1    Flores, E.2    Callejas, M.3
  • 26
    • 33646539811 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: A clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial
    • Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006;107:4047-4052.
    • (2006) Blood , vol.107 , pp. 4047-4052
    • Oschlies, I.1    Klapper, W.2    Zimmermann, M.3
  • 27
    • 84859715609 scopus 로고    scopus 로고
    • Roles of BCL6 in normal and transformed germinal center B cells
    • Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev. 2012;247:172-183.
    • (2012) Immunol Rev , vol.247 , pp. 172-183
    • Basso, K.1    Dalla-Favera, R.2
  • 28
    • 84894195316 scopus 로고    scopus 로고
    • Targeting BCL6 in diffuse large B-cell lymphoma: What does this mean for the future treatment?
    • Cerchietti L, Melnick A. Targeting BCL6 in diffuse large B-cell lymphoma: What does this mean for the future treatment? Expert Rev Hematol. 2013;6:343-345.
    • (2013) Expert Rev Hematol , vol.6 , pp. 343-345
    • Cerchietti, L.1    Melnick, A.2
  • 29
    • 77950486830 scopus 로고    scopus 로고
    • A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo
    • Cerchietti LC, Ghetu AF, Zhu X, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010;17:400-411.
    • (2010) Cancer Cell , vol.17 , pp. 400-411
    • Cerchietti, L.C.1    Ghetu, A.F.2    Zhu, X.3
  • 30
    • 79952430906 scopus 로고    scopus 로고
    • Inactivating mutations of acetyltransferase genes in B-cell lymphoma
    • Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189-195.
    • (2011) Nature , vol.471 , pp. 189-195
    • Pasqualucci, L.1    Dominguez-Sola, D.2    Chiarenza, A.3
  • 31
    • 0043170892 scopus 로고    scopus 로고
    • BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells
    • Kurosu T, Fukuda T, Miki T, Miura O. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene. 2003;22:4459-4468.
    • (2003) Oncogene , vol.22 , pp. 4459-4468
    • Kurosu, T.1    Fukuda, T.2    Miki, T.3    Miura, O.4
  • 32
    • 77951045229 scopus 로고    scopus 로고
    • The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
    • Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115:3017-3024.
    • (2010) Blood , vol.115 , pp. 3017-3024
    • Dunleavy, K.1    Little, R.F.2    Pittaluga, S.3
  • 33
    • 75749124332 scopus 로고    scopus 로고
    • Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
    • Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181-185.
    • (2010) Nat Genet , vol.42 , pp. 181-185
    • Morin, R.D.1    Johnson, N.A.2    Severson, T.M.3
  • 34
    • 67650398258 scopus 로고    scopus 로고
    • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
    • Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069-6076.
    • (2009) Blood , vol.113 , pp. 6069-6076
    • Dunleavy, K.1    Pittaluga, S.2    Czuczman, M.S.3
  • 35
    • 84862152044 scopus 로고    scopus 로고
    • Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
    • Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723-737.
    • (2012) Cancer Cell , vol.21 , pp. 723-737
    • Yang, Y.1    Shaffer III, A.L.2    Emre, N.C.3
  • 36
    • 80053502780 scopus 로고    scopus 로고
    • Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
    • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058-5066.
    • (2011) Cancer , vol.117 , pp. 5058-5066
    • Hernandez-Ilizaliturri, F.J.1    Deeb, G.2    Zinzani, P.L.3
  • 37
    • 73849145729 scopus 로고    scopus 로고
    • Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
    • Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88-92.
    • (2010) Nature , vol.463 , pp. 88-92
    • Davis, R.E.1    Ngo, V.N.2    Lenz, G.3
  • 38
    • 41149136296 scopus 로고    scopus 로고
    • Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
    • Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319:1676-1679.
    • (2008) Science , vol.319 , pp. 1676-1679
    • Lenz, G.1    Davis, R.E.2    Ngo, V.N.3
  • 39
    • 79551686422 scopus 로고    scopus 로고
    • Oncogenically active MYD88 mutations in human lymphoma
    • Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115-119.
    • (2011) Nature , vol.470 , pp. 115-119
    • Ngo, V.N.1    Young, R.M.2    Schmitz, R.3
  • 40
    • 84874585216 scopus 로고    scopus 로고
    • The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, phase 2 study
    • ASH Annual Meeting Abstracts, abstr 686
    • Wilson W, Gerecitano J, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood; ASH Annual Meeting Abstracts. 2012;120:abstr 686.
    • (2012) Blood , vol.120
    • Wilson, W.1    Gerecitano, J.2    Goy, A.3
  • 41
    • 84857640749 scopus 로고    scopus 로고
    • Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first line treatment of patients with intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) - preliminary analysis
    • Abstr 074
    • Hainsworth JD, Arrowsmith ER, Mccleod M, et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first line treatment of patients with intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) - preliminary analysis. Ann Oncol. 2011;22(suppl 4):Abstr 074.
    • (2011) Ann Oncol , vol.22 , Issue.SUPPL. 4
    • Hainsworth, J.D.1    Arrowsmith, E.R.2    McCleod, M.3
  • 42
    • 77951002653 scopus 로고    scopus 로고
    • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578-2585.
    • (2010) Blood , vol.115 , pp. 2578-2585
    • Friedberg, J.W.1    Sharman, J.2    Sweetenham, J.3
  • 43
    • 78149239933 scopus 로고    scopus 로고
    • Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium
    • Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol. 2010;28:4740-4746.
    • (2010) J Clin Oncol , vol.28 , pp. 4740-4746
    • Smith, S.M.1    van Besien, K.2    Karrison, T.3
  • 44
    • 23944481410 scopus 로고    scopus 로고
    • Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    • Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356.
    • (2005) J Clin Oncol , vol.23 , pp. 5347-5356
    • Witzig, T.E.1    Geyer, S.M.2    Ghobrial, I.3
  • 45
    • 78751553221 scopus 로고    scopus 로고
    • CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
    • Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2010;117:591-594.
    • (2010) Blood , vol.117 , pp. 591-594
    • Lannutti, B.J.1    Meadows, S.A.2    Herman, S.E.M.3
  • 46
    • 57849149430 scopus 로고    scopus 로고
    • Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    • Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia. 2008;22:2226-2229.
    • (2008) Leukemia , vol.22 , pp. 2226-2229
    • Klapper, W.1    Stoecklein, H.2    Zeynalova, S.3
  • 47
    • 70449589073 scopus 로고    scopus 로고
    • MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    • Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533-3537.
    • (2009) Blood , vol.114 , pp. 3533-3537
    • Savage, K.J.1    Johnson, N.A.2    Ben-Neriah, S.3
  • 48
    • 84867088456 scopus 로고    scopus 로고
    • Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    • Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452-3459.
    • (2012) J Clin Oncol , vol.30 , pp. 3452-3459
    • Johnson, N.A.1    Slack, G.W.2    Savage, K.J.3
  • 49
    • 84879385620 scopus 로고    scopus 로고
    • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program
    • Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021-4031.
    • (2013) Blood , vol.121 , pp. 4021-4031
    • Hu, S.1    Xu-Monette, Z.Y.2    Tzankov, A.3
  • 50
    • 84876222028 scopus 로고    scopus 로고
    • Selective inhibition of tumor oncogenes by disruption of super-enhancers
    • Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320-334.
    • (2013) Cell , vol.153 , pp. 320-334
    • Loven, J.1    Hoke, H.A.2    Lin, C.Y.3
  • 51
    • 84901851987 scopus 로고    scopus 로고
    • Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
    • un 24. [Epub ahead of print]
    • Tolani B, Gopalakrishnan R, Punj V, et al. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene. 2013 Jun 24. [Epub ahead of print]
    • (2013) Oncogene
    • Tolani, B.1    Gopalakrishnan, R.2    Punj, V.3
  • 52
    • 84055217904 scopus 로고    scopus 로고
    • Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma
    • Dunleavy K, Wilson WH. Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma. Clin Cancer Res. 2011;17:7505-7507.
    • (2011) Clin Cancer Res , vol.17 , pp. 7505-7507
    • Dunleavy, K.1    Wilson, W.H.2
  • 53
    • 0031018994 scopus 로고    scopus 로고
    • Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
    • Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood. 1997;89:601-609.
    • (1997) Blood , vol.89 , pp. 601-609
    • Wilson, W.H.1    Teruya-Feldstein, J.2    Fest, T.3
  • 54
    • 0030985194 scopus 로고    scopus 로고
    • Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
    • Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251.
    • (1997) Blood , vol.90 , pp. 244-251
    • Gascoyne, R.D.1    Adomat, S.A.2    Krajewski, S.3
  • 55
    • 78649630259 scopus 로고    scopus 로고
    • Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
    • Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149-1159.
    • (2010) Lancet Oncol , vol.11 , pp. 1149-1159
    • Wilson, W.H.1    O'Connor, O.A.2    Czuczman, M.S.3
  • 56
    • 84873540049 scopus 로고    scopus 로고
    • ABT-99, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
    • Souers AJ, Leverson JD, Boghaert ER, et al. ABT-99, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202-8.
    • (2013) Nat Med , vol.19 , pp. 202-208
    • Souers, A.J.1    Leverson, J.D.2    Boghaert, E.R.3
  • 57
    • 0033571348 scopus 로고    scopus 로고
    • Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients
    • Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999;94:3289-93.
    • (1999) Blood , vol.94 , pp. 3289-3293
    • Zinzani, P.L.1    Martelli, M.2    Magagnoli, M.3
  • 58
    • 0037567428 scopus 로고    scopus 로고
    • Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    • Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-95.
    • (2003) N Engl J Med , vol.348 , pp. 2386-2395
    • Diehl, V.1    Franklin, J.2    Pfreundschuh, M.3
  • 59
    • 10744224539 scopus 로고    scopus 로고
    • Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B
    • Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90:372-6.
    • (2004) Br J Cancer , vol.90 , pp. 372-376
    • Todeschini, G.1    Secchi, S.2    Morra, E.3
  • 60
    • 0036906427 scopus 로고    scopus 로고
    • Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients
    • Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258-64.
    • (2002) Haematologica , vol.87 , pp. 1258-1264
    • Zinzani, P.L.1    Martelli, M.2    Bertini, M.3
  • 61
    • 27244432753 scopus 로고    scopus 로고
    • Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
    • Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol. 2005;130:691-9.
    • (2005) Br J Haematol , vol.130 , pp. 691-699
    • Hamlin, P.A.1    Portlock, C.S.2    Straus, D.J.3
  • 62
    • 29844432120 scopus 로고    scopus 로고
    • Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience
    • Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17:123-30.
    • (2006) Ann Oncol , vol.17 , pp. 123-130
    • Savage, K.J.1    Al-Rajhi, N.2    Voss, N.3
  • 63
    • 79952029773 scopus 로고    scopus 로고
    • Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the MabThera International Trial Group study
    • Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the MabThera International Trial Group study. Ann Oncol. 2011;22:664-70.
    • (2011) Ann Oncol , vol.22 , pp. 664-670
    • Rieger, M.1    Osterborg, A.2    Pettengell, R.3
  • 64
    • 84857386754 scopus 로고    scopus 로고
    • Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: The emerging standard of care
    • Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17:239-49.
    • (2012) Oncologist , vol.17 , pp. 239-249
    • Vassilakopoulos, T.P.1    Pangalis, G.A.2    Katsigiannis, A.3
  • 65
    • 84894480056 scopus 로고    scopus 로고
    • Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
    • Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55:538-43.
    • (2014) Leuk Lymphoma , vol.55 , pp. 538-543
    • Soumerai, J.D.1    Hellmann, M.D.2    Feng, Y.3
  • 66
    • 79951492419 scopus 로고    scopus 로고
    • Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study
    • Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806-16.
    • (2011) Blood , vol.117 , pp. 1806-1816
    • Castellino, S.M.1    Geiger, A.M.2    Mertens, A.C.3
  • 67
    • 79951495388 scopus 로고    scopus 로고
    • Sobering realities of surviving Hodgkin lymphoma
    • Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin lymphoma. Blood. 2011;117:1772-3.
    • (2011) Blood , vol.117 , pp. 1772-1773
    • Dunleavy, K.1    Bollard, C.M.2
  • 68
    • 77949887677 scopus 로고    scopus 로고
    • Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy
    • O'Brien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28:1232-9.
    • (2010) J Clin Oncol , vol.28 , pp. 1232-1239
    • O'Brien, M.M.1    Donaldson, S.S.2    Balise, R.R.3
  • 69
    • 45749152667 scopus 로고    scopus 로고
    • Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    • Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26:2717-24.
    • (2008) J Clin Oncol , vol.26 , pp. 2717-2724
    • Wilson, W.H.1    Dunleavy, K.2    Pittaluga, S.3
  • 70
    • 79951534002 scopus 로고    scopus 로고
    • Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103
    • Abstr 6530
    • Wilson WH, Porcu P, Hurd D, et al. Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. J Clin Oncol. 2005;23(suppl 16S):Abstr 6530.
    • (2005) J Clin Oncol , vol.23 , Issue.SUPPL. 16
    • Wilson, W.H.1    Porcu, P.2    Hurd, D.3
  • 71
    • 84875962936 scopus 로고    scopus 로고
    • Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma
    • Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408-16.
    • (2013) N Engl J Med , vol.368 , pp. 1408-1416
    • Dunleavy, K.1    Pittaluga, S.2    Maeda, L.S.3
  • 72
    • 84880400434 scopus 로고    scopus 로고
    • Therapy in primary mediastinal B-cell lymphoma
    • Woessmann W, Lisfeld J, Burkhardt B. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;369:282-3.
    • (2013) N Engl J Med , vol.369 , pp. 282-283
    • Woessmann, W.1    Lisfeld, J.2    Burkhardt, B.3
  • 73
    • 84884260608 scopus 로고    scopus 로고
    • STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)
    • Ritz O, Rommel K, Dorsch K, et al. STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget. 2013;4:1093-102.
    • (2013) Oncotarget , vol.4 , pp. 1093-1102
    • Ritz, O.1    Rommel, K.2    Dorsch, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.